Emergence of De Novo Conditions Following Remission of Cushing Syndrome: A Case Report and Scoping Review

• Published in: Endocrinology, diabetes & metabolism Vol. 7; no. 3; pp. e00476 - n/a
• Main Authors: Desgagnés, Noémie, Senior, Laura, Vis, Daniel, Alikhani, Katayoun, Lithgow, Kirstie
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.05.2024; John Wiley and Sons Inc; Wiley
• Subjects: Abdomen; Adrenal Insufficiency - complications; Adult; autoimmune diseases; Case reports; Cushing syndrome; Cushing Syndrome - complications; Cushing Syndrome - surgery; Glucocorticoids; Hormones; Humans; Male; Metastasis; Remission (Medicine); Sarcoidosis; Sarcoidosis - complications; Sarcoidosis - diagnosis; Steroids; Surgery; thyroiditis; Tumors; autoimmune diseases; Cushing syndrome; sarcoidosis; thyroiditis; glucocorticoids; adult; humans
• ISSN: 2398-9238; 2398-9238
• DOI: 10.1002/edm2.476

ABSTRACT Objective Onset and exacerbation of autoimmune, inflammatory or steroid‐responsive conditions have been reported following the remission of Cushing syndrome, leading to challenges in distinguishing a new condition versus expected symptomatology following remission. We describe a case of a 42‐year‐old man presenting with new‐onset sarcoidosis diagnosed 12 months following the surgical cure of Cushing syndrome and synthesise existing literature reporting on de novo conditions presenting after Cushing syndrome remission. Methods A scoping review was conducted in Medline, Epub, Ovid and PubMed. Case reports and case series detailing adult patients presenting with new‐onset conditions following Cushing syndrome remission were included. Results In total, 1641 articles were screened, 138 full‐text studies were assessed for eligibility, and 43 studies were included, of which 84 cases (including our case) were identified. Most patients were female (85.7%), and the median reported age was 39.5 years old (IQR = 13). Thyroid diseases were the most commonly reported conditions (48.8%), followed by sarcoidosis (15.5%). Psoriasis, lymphocytic hypophysitis, idiopathic intracranial hypertension, multiple sclerosis, rheumatoid arthritis, lupus and seronegative arthritis were reported in more than one case. The median duration between Cushing remission and de novo condition diagnosis was 4.1 months (IQR = 3.75). Of those patients, 59.5% were receiving corticosteroid therapy at the time of onset. Conclusion Our scoping review identified several cases of de novo conditions emerging following the remission of Cushing syndrome. They occurred mostly in women and within the year following remission. Clinicians should remain aware that new symptoms, particularly in the first year following the treatment of Cushing syndrome, may be manifestations of a wide range of conditions aside from adrenal insufficiency or glucocorticoid withdrawal syndrome. Onset and exacerbation of autoimmune, inflammatory or steroid‐responsive conditions have been reported following the remission of Cushing syndrome, leading to challenges in distinguishing a new condition versus expected symptomatology following remission. We describe a case of a 42‐year‐old man presenting with new‐onset sarcoidosis diagnosed 12 months following the surgical cure of Cushing syndrome and synthesise the existing literature reporting on de novo conditions presenting after Cushing syndrome remission. Our scoping review identified several cases de novo conditions emerging following the remission of Cushing syndrome occurring mostly in women and within the year following remission.